Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.
(2002) In European Neuropsychopharmacology 12(4). p.327-336- Abstract
- Patients with chronic hepatic encephalopathy (HE) may present affective symptoms and antidepressant drug treatment in this condition is not uncommon. The present microdialysis study investigated treatment with the chronic antidepressant venlafaxine (VEN) in experimental HE with regard to tentative changes in pharmacokinetic and/or pharmacodynamic parameters. Three weeks after portacaval shunt (PCS) or sham operation in rats, VEN (10 mg/kg daily) was administered by implanted osmotic minipumps. VEN treatment for 14 days resulted in higher concentrations of VEN in PCS rats than in sham controls in serum and brain compartments, and the VEN levels in serum and brain were strongly inter-correlated. The serum N-desmethylvenlafaxine concentration... (More)
- Patients with chronic hepatic encephalopathy (HE) may present affective symptoms and antidepressant drug treatment in this condition is not uncommon. The present microdialysis study investigated treatment with the chronic antidepressant venlafaxine (VEN) in experimental HE with regard to tentative changes in pharmacokinetic and/or pharmacodynamic parameters. Three weeks after portacaval shunt (PCS) or sham operation in rats, VEN (10 mg/kg daily) was administered by implanted osmotic minipumps. VEN treatment for 14 days resulted in higher concentrations of VEN in PCS rats than in sham controls in serum and brain compartments, and the VEN levels in serum and brain were strongly inter-correlated. The serum N-desmethylvenlafaxine concentration did not differ between the groups, but correlated with the serum VEN levels. The other VEN metabolites were below the quantification limits. VEN treatment for 9-12 days significantly stimulated locomotion and rearing in the open field in sham controls, but failed to do so in the PCS rats. The concentrations of noradrenaline, dopamine, 5-HT, and 5-HIAA in neocortical dialysates were higher in PCS than in sham rats after 14 days of VEN treatment, but the elevations reached statistical significance only in the case of dopamine and 5-HIAA. In summary, there were significant pharmacokinetic and pharmacodynamic alterations in rats with experimental HE as compared to controls. The described experimental HE model may be useful for continued pharmacokinetic/pharmacodynamic interaction studies to unravel the pathophysiological consequences of HE on the CNS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/109499
- author
- Wikell, Cecilia LU ; Apelqvist, Gustav ; Hjorth, Stephan ; Kullingsjö, Johan ; Bergqvist, Peter B F and Bengtsson, Finn
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Neuropsychopharmacology
- volume
- 12
- issue
- 4
- pages
- 327 - 336
- publisher
- Elsevier
- external identifiers
-
- wos:000177640300008
- pmid:12126872
- scopus:0036019861
- ISSN
- 1873-7862
- DOI
- 10.1016/S0924-977X(02)00044-5
- language
- English
- LU publication?
- yes
- id
- 80ae1f4a-6b3f-4e1d-be5e-d5b11bd413d0 (old id 109499)
- alternative location
- http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12126872&dopt=Abstract
- date added to LUP
- 2016-04-01 12:19:39
- date last changed
- 2022-01-27 02:07:15
@article{80ae1f4a-6b3f-4e1d-be5e-d5b11bd413d0,
abstract = {{Patients with chronic hepatic encephalopathy (HE) may present affective symptoms and antidepressant drug treatment in this condition is not uncommon. The present microdialysis study investigated treatment with the chronic antidepressant venlafaxine (VEN) in experimental HE with regard to tentative changes in pharmacokinetic and/or pharmacodynamic parameters. Three weeks after portacaval shunt (PCS) or sham operation in rats, VEN (10 mg/kg daily) was administered by implanted osmotic minipumps. VEN treatment for 14 days resulted in higher concentrations of VEN in PCS rats than in sham controls in serum and brain compartments, and the VEN levels in serum and brain were strongly inter-correlated. The serum N-desmethylvenlafaxine concentration did not differ between the groups, but correlated with the serum VEN levels. The other VEN metabolites were below the quantification limits. VEN treatment for 9-12 days significantly stimulated locomotion and rearing in the open field in sham controls, but failed to do so in the PCS rats. The concentrations of noradrenaline, dopamine, 5-HT, and 5-HIAA in neocortical dialysates were higher in PCS than in sham rats after 14 days of VEN treatment, but the elevations reached statistical significance only in the case of dopamine and 5-HIAA. In summary, there were significant pharmacokinetic and pharmacodynamic alterations in rats with experimental HE as compared to controls. The described experimental HE model may be useful for continued pharmacokinetic/pharmacodynamic interaction studies to unravel the pathophysiological consequences of HE on the CNS.}},
author = {{Wikell, Cecilia and Apelqvist, Gustav and Hjorth, Stephan and Kullingsjö, Johan and Bergqvist, Peter B F and Bengtsson, Finn}},
issn = {{1873-7862}},
language = {{eng}},
number = {{4}},
pages = {{327--336}},
publisher = {{Elsevier}},
series = {{European Neuropsychopharmacology}},
title = {{Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.}},
url = {{http://dx.doi.org/10.1016/S0924-977X(02)00044-5}},
doi = {{10.1016/S0924-977X(02)00044-5}},
volume = {{12}},
year = {{2002}},
}